Kura Oncology, Inc. (KURA - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on KURA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Kura Oncology could be a solid choice for investors.
Current Quarter Estimates for KURA
In the past 30 days, the trend has been pretty favorable, with estimates narrowing from a loss of 41 cents a share 30 days ago, to a loss of 37 cents today, a move of 9.8%.
Current Year Estimates for KURA
Meanwhile, Kura Oncology’s current year figures are also looking quite promising, with the consensus estimate trend narrowing from a loss of $1.64 per share 30 days ago to a loss of $1.54 per share today, a move of 6.1%.
The stock has also started to move higher lately, adding 100.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
New Report: An Investor’s Guide to Cybersecurity
Cyberattacks have become more frequent and destructive than ever. In fact, they’re expected to cause $6 trillion per year in damage by 2020.
The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor’s Guide to Locking Down Profits which reveals 4 promising investment candidates.
Download the new report now>>